Caresyntax announced today that it raised $180 million through a Series C financing extension and growth debt expansion round.
Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund and ProAssurance Corp. all contributed to the round. Caresyntax raised $80 million in equity and up to $100 million in growth debt.
The San Francisco-based vendor-neutral precision surgery platform developer aims to transform surgery with a scalable, end-to-end software and AI platform. Caresyntax’s medical-grde, interoperable platform allows for the capture and use of novel data and applications. It helps enhance surgical precision and patient safety.
According to a news release, the platform also address critical data shortfall and fragmentation challenges. These can hinder the progress of precision and data-assisted surgery.
Caresyntax leverages tech and AI to collect, integrate and analyze unique and comprehensive data. Its platform delivers real-time, long-term clinical decision support that enhances the patient journey. The technology also boosts hospital operational efficiency and drives better patient outcomes and profitability.
Together with our partners and investors, we are working towards deploying precision surgical tools, empowered by data and AI, to improve patient outcomes,” said Dennis Kogan, co-founder and CEO of Caresyntax. “This financing is not just an investment in Caresyntax, but an investment in the future of surgery. My gratitude extends to our investors who contribute to and believe in the power of smart data and AI usage in the operating room.”
